CURRENT OPPORTUNITES
This company has developed a rapid Anti-Susceptibility Testing system that with change the diagnostic world within the healthcare industry. Currently, the Gold-standard Phenotypic Antimicrobial Susceptibility Testing (AST) results are one of the most labor-intensive activities in a clinical microbiology lab and the results are notoriously slow, taking days. While doctors wait, hospital bills increase and patients suffer - or the results are too late to make a difference and the patient perishes. Acenxion’s proprietary technology has effectively reduced that processing time from days to hours. It will be the new Gold standard. BARDA, WHO and the NIH agree as the company has just been informed (Jan 2021) they have been awarded a $3M grant from the NIH
